tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Melanoma D008545 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Precancerous Conditions D011230 48 associated lipids
Fatty Liver D005234 48 associated lipids
Psoriasis D011565 47 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Leukemia P388 D007941 43 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Whalen HR et al. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. 2017 Transplantation pmid:26950724
Keenan RJ et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. 1991 Transplantation pmid:1719668
Shin BH et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. 2014 Transplantation pmid:24342979
Yoon SH et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). 2013 Transplantation pmid:23364483
Rolles K et al. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. 1999 Transplantation pmid:10551650
Koneru B et al. Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? 1997 Transplantation pmid:9197350
Sugitani A et al. En bloc pancreas and kidney transplantation in a patient with limited vascular access. 1997 Transplantation pmid:9197366
Lykavieris P et al. Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. 2003 Transplantation pmid:12544888
Lawsin L and Light JA Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. 2003 Transplantation pmid:12544890
Furukawa H et al. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. 2000 Transplantation pmid:10670633
Furukawa H et al. The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. 1992 Transplantation pmid:1373531
Sakr M et al. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients. 1992 Transplantation pmid:1373535
Hoffman AL et al. The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. 1990 Transplantation pmid:1690469
Weir MR et al. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. 2017 Transplantation pmid:26950714
Ueno P et al. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. 2017 Transplantation pmid:27490418
Ravindran VK et al. Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation. 2009 Transplantation pmid:19543067
Loucaidou M et al. Five-year results of kidney transplantation under tacrolimus-based regimes: the persisting significance of vascular rejection. 2003 Transplantation pmid:14557763
Toso C et al. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients. 2003 Transplantation pmid:14557767
Vu MD et al. Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. 2003 Transplantation pmid:12792496
Tzakis AG et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. 2003 Transplantation pmid:12792506
Koenen HJ et al. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. 2003 Transplantation pmid:12792519
Nicolai S and Bunyavanich S Hypersensitivity reaction to intravenous but not oral tacrolimus. 2012 Transplantation pmid:23128975
Barth RN et al. Prolonged survival of composite facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder. 2009 Transplantation pmid:19996923
First MR Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population. 2001 Transplantation pmid:11585240
Tarumi K et al. CTLA4IgG treatment induces long-term acceptance of rat small bowel allografts. 1999 Transplantation pmid:10071020
Mourad G et al. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial. 2017 Transplantation pmid:27547871
Pirsch JD et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9112351
Tanabe M et al. Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. 1994 Transplantation pmid:7518619
Jain A et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. 2000 Transplantation pmid:10972220
Wang SC et al. A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. 1993 Transplantation pmid:7692640
Khanna AK Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. 2000 Transplantation pmid:10972232
Königsrainer A et al. Nonocclusive segmental mesenteric ischemia after combined pancreas kidney transplantation: mycophenolate mofetil as an etiological factor? 2000 Transplantation pmid:10972233
Butani L et al. Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. 2003 Transplantation pmid:12883183
David-Neto E et al. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. 2017 Transplantation pmid:27482958
Marcén R et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. 2006 Transplantation pmid:16570003
Heilman RL et al. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. 2011 Transplantation pmid:21775930
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. 2006 Transplantation pmid:16570006
Sood P et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. 2012 Transplantation pmid:23018881
Alonso-Arias R et al. CD127(low) expression in CD4+CD25(high) T cells as immune biomarker of renal function in transplant patients. 2009 Transplantation pmid:19667968
Galliford J et al. ABO incompatible living renal transplantation with a steroid sparing protocol. 2008 Transplantation pmid:18852653
Jevnikar A et al. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. 2008 Transplantation pmid:18852662
Yamazaki S et al. Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. 2008 Transplantation pmid:18852671
Batten P et al. Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro. 1999 Transplantation pmid:10589954
Dickenmann MJ et al. Blood eosinophilia in tacrolimus-treated patients: an indicator of Pneumocystis carinii pneumonia. 1999 Transplantation pmid:10589963
Eckhoff DE et al. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. 1998 Transplantation pmid:9458011
Naesens M and Sarwal MM Monitoring calcineurin inhibitor therapy: localizing the moving target. 2010 Transplantation pmid:20458272
Kaufman DB et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. 1995 Transplantation pmid:7541579
Bolin P et al. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results. 2008 Transplantation pmid:18622283
Herlenius G et al. Chronic kidney disease--a common and serious complication after intestinal transplantation. 2008 Transplantation pmid:18622286
Ceulemans LJ et al. Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. 2015 Transplantation pmid:25695790
Watson MJ et al. Renal function impacts outcomes after intestinal transplantation. 2008 Transplantation pmid:18622288
Thorp M et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. 2000 Transplantation pmid:10762229
Miyazawa H et al. Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. 1995 Transplantation pmid:7537396
Irish W et al. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. 2003 Transplantation pmid:14688516
Fujii Y et al. Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. 1989 Transplantation pmid:2472025
Chisholm MA et al. Coadministration of tacrolimus with anti-acid drugs. 2003 Transplantation pmid:12973105
Richards KR et al. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. 2014 Transplantation pmid:24784360
McDiarmid SV et al. Factors affecting growth after pediatric liver transplantation. 1999 Transplantation pmid:10030286
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. 1999 Transplantation pmid:10030287
Amundsen R et al. Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. 2009 Transplantation pmid:19384170
Klupp J et al. Indications of mycophenolate mofetil in liver transplantation. 2005 Transplantation pmid:16286893
Jun KR et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. 2009 Transplantation pmid:19384171
Vafadari R et al. Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry. 2012 Transplantation pmid:22643331
Ji E et al. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. 2012 Transplantation pmid:22992768
Ericzon BG et al. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. 1997 Transplantation pmid:9000664
Kelly PA et al. Ciprofloxacin does not block the antiproliferative effect of tacrolimus. 1997 Transplantation pmid:9000686
Morales JM et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. 2008 Transplantation pmid:18724234
Gallon LG et al. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. 2007 Transplantation pmid:17519781
Tamura K et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. 1995 Transplantation pmid:7539960
Shaefer MS et al. Falsely elevated FK-506 levels caused by sampling through central venous catheters. 1993 Transplantation pmid:7689264
Fisher A et al. FK506 hepatotoxicity in liver allograft recipients. 1995 Transplantation pmid:7539961
Fukushima D et al. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. 2015 Transplantation pmid:24846306
Valdivia LA et al. Dendritic cell replacement in long-surviving liver and cardiac xenografts. 1993 Transplantation pmid:7689265
Hardinger KL et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. 2005 Transplantation pmid:16003231
MacDonald A Improving tolerability of immunosuppressive regimens. 2001 Transplantation pmid:11833142
Wang K et al. Transplantation of infantile bladder in rats: an alternative procedure for bladder augmentation. 2001 Transplantation pmid:11213059
Egli A et al. Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. 2013 Transplantation pmid:23274966
Molleví DG et al. Heart and liver xenotransplantation under low-dose tacrolimus: graft survival after withdrawal of immunosuppression. 2001 Transplantation pmid:11213062
Wennberg L et al. The efficacy of CD40 ligand blockade in discordant pig-to-rat islet xenotransplantation is correlated with an immunosuppressive effect of immunoglobulin. 2005 Transplantation pmid:15665763
Hebert MF et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. 2013 Transplantation pmid:23274970
Gruessner RW et al. Donor-specific portal blood transfusion in intestinal transplantation: a prospective, preclinical large animal study. 1998 Transplantation pmid:9701258
Danziger-Isakov LA et al. The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation. 2009 Transplantation pmid:19461492
Fujishiro J et al. Immunologic benefits of longer graft in rat allogenic small bowel transplantation. 2005 Transplantation pmid:15665767
Raggi MC et al. Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. 2010 Transplantation pmid:21076373
Thai NL et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. 2006 Transplantation pmid:17198247
Thai NL et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. 2006 Transplantation pmid:17198253
Konrad T et al. Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus therapy. 2000 Transplantation pmid:10852599
Pirenne J et al. Combined transplantation of small and large bowel. FK506 versus cyclosporine A in a porcine model. 1996 Transplantation pmid:8685944
Schvarcz R et al. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). 2000 Transplantation pmid:10852623
Tsugita M et al. Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. 1996 Transplantation pmid:8685952
Lake JR et al. The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial. 1995 Transplantation pmid:7482713
Mathew A et al. Reversal of steroid-resistant rejection in renal allograft recipients using FK506. 1995 Transplantation pmid:7482730
Stephen M et al. Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. 1989 Transplantation pmid:2463701
Aisa Y et al. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. 2005 Transplantation pmid:16278584
Vítko S et al. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. 2005 Transplantation pmid:16378069
Vacher-Coponat H et al. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. 2012 Transplantation pmid:22228415
Tanaka J et al. The immunosuppressive agent FK506 enhances the cytolytic activity of inhibitory natural killer cell receptor (CD94/NKG2A)-expressing CD8 T cells. 2005 Transplantation pmid:16378079
Wang HD et al. Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. 2018 Transplantation pmid:29298238
Dharancy S et al. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. 2007 Transplantation pmid:17460561
Vadivel N et al. Tacrolimus dose in black renal transplant recipients. 2007 Transplantation pmid:17460575